NextCell Pharma AB: NextCell publishes its Year-End Report 2023/2024

Fourth quarter (2024-06-01 until 2024-08-31)

• Operating income amounted to 1,696 (3,947) TSEK, of which Cellaviva amounted to 1,643 (2,758) TSEK.
• Net Income amounted to 1,643 (2,758) SEK
• Operating result amounted to -13,249 (-8,640) TSEK.
• Earnings per share* amounted to -0.22 (-0.25) SEK.
• Cash and Bank amounted to 46,791 (50,025) TSEK.
• Solidity** amounted to 83.8 (85.3) percent.

 

Twelve months (2023-09-01 till 2024-08-31)

• Operating income amounted to 11,278 (13,955) TSEK, of which Cellaviva amounted to 10,665 (10,113) TSEK.
• Net Income amounted to 10,665 (10,113) SEK
• Operating result amounted to -41,960 (-39,812) TSEK.
• Earnings per share* amounted to -1.03 (-1.16) SEK.
• The Board of Directors proposes that no dividend shall be paid for the financial year.

 

Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the fourth quarter 2023/2024: 59,979,085 (34,379,523) shares. Number of shares in NextCell as of August 31, 2024: 73,091,327 (34,379,523) shares.

**Solidity: Equity to total balance sheet.

Significant events in the fourth quarter

• At the beginning of June, NextCell announced that the Company had agreed on a so-called top guarantee of a total of approximately SEK 8.0 million, corresponding to approximately 20.0 percent of the issue volume. Through the additional top guarantee, the Rights Issue is covered up to approximately 100 percent by subscription and guarantee commitments.

 

• At the beginning of June, NextCell announced that the company's Board of Directors, management and key employees, who have previously entered into subscription commitments of up to a total of approximately SEK 1.5 million, announced that they will register their interest in subscribing for units for a total of approximately SEK 3.3 million, corresponding to 8.2 percent of the rights issue.
• The company announced in mid-June that the Data Safety Monitoring Board for the ProTrans-Young study had recommended the principal investigator, Professor Per-Ola Carlsson, to continue with treatment of children in the younger age group 7-11 years. This decision is based on a review of all safety data from the 36 children and adolescents who have participated in the study so far. The recruitment of the 30 children aged 7-11 will begin in August 2024.
• In mid-June, NextCell announced the outcome of the rights issue. The rights issue was oversubscribed and NextCell will receive approximately SEK 40.1 million before deduction of issue costs.
• At the beginning of July, NextCell announced that it is carrying out a directed share issue to guarantors in connection with the completed rights issue, corresponding to 894,232 units, which reduces the guarantee compensation by approximately SEK 1.34 million.

 

Significant after the fourth quarter

• At the beginning of September, the company presented new long-term clinical data at the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting. The results show the long-term safety of the treatment, efficacy by preserving endogenous insulin production and more health benefits in patients of patients with type 1 diabetes (T1D) such as lower BMI and blood pressure.

 

• At the end of September, the company announced that the first four children in the age group 7-11 years had been treated in the latest part of the ProTrans-Young study, and that four more children had been screened and are expected to start their treatment shortly. These advances mark an important milestone in the course of the study that is progressing faster than expected.

 

• The company announced in early October that ProTrans was highlighted as a promising treatment for type 1 diabetes in Dagens Medicin.

 

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 24-10-2024 07:30 CET.